Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease

Background: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted...

Full description

Bibliographic Details
Main Authors: Viktoria Bergqvist, Mohammad Kadivar, Daniel Molin, Leif Angelison, Per Hammarlund, Marie Olin, Jörgen Torp, Olof Grip, Stefan Nilson, Erik Hertervig, Jan Lillienau, Jan Marsal
Format: Article
Language:English
Published: SAGE Publishing 2018-10-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284818801244

Similar Items

Similar Items